<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621490</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-038</org_study_id>
    <secondary_id>2012-001840-23</secondary_id>
    <nct_id>NCT01621490</nct_id>
  </id_info>
  <brief_title>PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma</brief_title>
  <acronym>PD-1</acronym>
  <official_title>An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab
      in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood
      and tumor tissues of subjects with advanced melanoma (unresectable or advanced)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation:

      Part 1 and 2: Single Arm study

      Part 3 and 4: Randomized Controlled Trial

      Intervention Model:

      Part 1 and 2: Single group: Single arm study

      Part 3 and 4: Parallel: Participants are assigned to one of two or more groups in parallel
      for the duration of the study

      Minimum Age:

      Part 1: 18

      Part 2, 3 and 4: 16
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 27, 2012</start_date>
  <completion_date type="Anticipated">December 2, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunomodulatory effects of Nivolumab and Nivolumab in combination with Ipilimumab as measured by changes from baseline in activated and memory T cells, interferon, interferon inducible factors, and CD4 and CD8 T cell infiltration</measure>
    <time_frame>Pre-dose day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunomodulatory effects of Nivolumab and Nivolumab in combination with Ipilimumab as measured by changes from baseline in activated and memory T cells, interferon, interferon inducible factors, and CD4 and CD8 T cell infiltration</measure>
    <time_frame>Up to day 57</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by the incidence of adverse events (AEs), serious AEs, death, and changes in vital signs</measure>
    <time_frame>Up to 100 days after last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by laboratory test abnormalities</measure>
    <time_frame>Every 2 or 3 weeks up to 100 days after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the objective response rate (ORR), duration of response, and progression free survival (PFS)</measure>
    <time_frame>Approximately every 8 weeks until disease progression and in follow-up if no progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the frequency of baseline positive subjects and the frequency of ADA positive subjects</measure>
    <time_frame>Up to follow-up visit 2 (101-120 days since last treatment)</time_frame>
    <description>Time Frame:
Part 1: Day 1, Day 15, Day 43 of cycle 1, Day 1 of cycle 2, Day 15 of cycle 3, every 16 weeks after cycle 3 up to 2 years, follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment)
Part 2, 3 and 4: Weeks 1, 3, 4, 7, 9, 10, 13, 25, 53, 79, 95 follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between Programmed cell death ligand 1 (PD-L1) and clinical efficacy will be measured by PDL1 expression levels clinical activity (ORR, PFS)</measure>
    <time_frame>Part 1: Pre-dose up to Day 1 (screening Day -7 to day 1 predose) and Day 29 of cycle 1. Part 2, 3 and 4: Pre-dose (screening Day -28 to Day 1 predose) and week 2 or 4</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">237</enrollment>
  <condition>Advanced Melanoma</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Part 1-Cohort 1 and 2: Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3-Arm B: Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4-Arm D: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4-Arm E: Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Part 1-Cohort 1 and 2: Nivolumab</arm_group_label>
    <arm_group_label>Part 2-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 3-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 3-Arm B: Nivolumab</arm_group_label>
    <arm_group_label>Part 4-Arm D: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 4-Arm E: Nivolumab</arm_group_label>
    <other_name>BMS-936558 (MDX1106)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Part 2-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 3-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 4-Arm D: Nivolumab + Ipilimumab</arm_group_label>
    <other_name>BMS734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Part 1:

        Inclusion Criteria:

          -  Men and women &gt;18 years

          -  Eastern Cooperative Oncology Group (ECOG) status = 0 to 1

          -  Subjects with unresectable Stage III or IV melanoma who are either refractory or
             intolerant to, or have refused standard therapy for treatment of metastatic melanoma

          -  Subject must have histologic or cytologic confirmation of advanced melanoma

          -  Subjects must have at least one measurable lesion at baseline by computed tomography
             (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1 criteria

          -  Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical
             risk and must consent to pre- and post-treatment biopsies

        Exclusion Criteria:

          -  Active or progressing brain metastases

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active or history of autoimmune disease

          -  Positive test for human immunodeficiency virus (HIV) 1&amp;2 or known acquired
             immunodeficiency syndrome (AIDS)

          -  History of any hepatitis

          -  Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
             including but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137,
             anti-OX-40,and anti-CD40 antibodies. However, half the patients must have progressed
             on anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) monoclonal antibody
             therapy

        Part 2, 3 and 4:

        Inclusion Criteria

          -  Men and women &gt;16 years

          -  Eastern Cooperative Oncology Group (ECOG) status = 0 to 1

          -  Subjects with unresectable Stage III or IV melanoma who are either refractory or
             intolerant to, or have refused standard therapy for treatment of metastatic melanoma

          -  Subjects must never received anti-CTLA4 therapy

          -  Subjects must have histologic or cytologic confirmation of advanced melanoma

          -  Subjects must have at least two measurable lesions at baseline by CT or MRI as per
             RECIST 1.1 criteria

          -  Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical
             risk and must consent to pre- and post-treatment biopsies

          -  Subjects in Part 4 must have brain metastases

        Exclusion Criteria

          -  Active or progressing brain metastases (except for Part 4 subjects)

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active or history of autoimmune disease

          -  Positive test for HIV 1&amp;2 or known AIDS

          -  History of any hepatitis

          -  Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
             including but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137,
             anti-OX-40,and anti-CD40 antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucla</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31192</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

